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Abstract
Background: Access to antiretroviral therapy (ART) has increased dramatically in Sub-Saharan Africa. In Kenya,
560,000 people had access to ART by the end of 2011. This scaling up of ART has raised challenges to the Kenyan
health system due to emergence of drug resistant viruses among those on treatment and possible onward
transmission. To counter this, and come up with an effective treatment strategy, it has become vital to determine
baseline mutations associated with drug resistance among the circulating strains of HIV-1in Kenya.
Methods: The prevalence of mutations associated with drug resistance in HIV-1 protease (PR) and reverse transcriptase
(RT) regions from 188 HIV-1 infected treatment-naïve pregnant women was investigated in Kapsabet, Nandi Hills and
Kitale district hospitals of Kenya. Blood samples were collected between April 2005 and June 2006. The HIV-1 pol gene
was amplified using primers for HIV-1 PR and RT and sequenced using the BigDye chemistry. The mutations were
analyzed based on the IAS algorithm as well as the Stanford University HIV Drug Resistance Database.
Results: Based on the PR and RT sequences, HIV-1 subtypes A1 (n=117, 62.2%), A2 (n=2, 1.1%), D (n=27, 14.4%),
C (n=13, 6.9%), G (n=3, 1.6%), and possible recombinants (n=26, 13.8%) were detected. Mutations associated with
nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside RTI (NNRTI)-resistance were detected in 1.6%
(3 of 188) and 1.1% (2 of 188), respectively. Mutations associated with PI resistance were detected in 0.5% (1 of 188) of
the study population.
Conclusion: The prevalence of drug resistance among drug-naïve pregnant women in rural North Rift, Kenya in 2006
was 3.2%. Major drug resistance mutations associated with PIs, NRTIs and NNRTIs do exist among treatment-naïve
pregnant women in North Rift, Kenya. There is a need for consistent follow-up of drug-naïve individuals in this region
to determine the impact of mutations on treatment outcomes.
Background
In Kenya, the first AIDS case was recognized in 1984 [1]
and since that time, HIV/AIDS still remains a huge barrier
to social and economic development. Currently, the over-
all country prevalence is estimated to be 6.3% for Kenyans
aged 15–49 years. About 1.5 million Kenyan adults are liv-
ing with HIV. One of the major responses to the HIV/
AIDS crisis in Kenya has been the introduction of a na-
tional policy for infected persons to access antiretroviral
therapy (ART). To implement this policy, the Kenya
National ARV program was established in 2002 to pro-
gressively deliver effective ARV, reaching 20% of patients
by 2005 and 50–60% by 2008. According to World Health
Organization (WHO) and Kenya National AIDS and STI
Control Programme (NASCOP), >60% of adult Kenyans
who were living with HIV and in need of ART were re-
ceiving it by the end of 2011 [2].
Gaining access to ART has implications in improving
the quality of life for people living with HIV/AIDS and
prevention of vertical transmission [3,4]. One of the
major obstacles in achieving the long-term efficacy of
ART is the development of resistance. In resource-limited
settings, adherence is a major contributing factor to* Correspondence: Mkiptoo@kemri.org1Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya
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development of drug resistance and ultimately treatment
failure [5].
Studies on drug resistance have been carried out ex-
tensively on HIV-1 clade B viruses, the prevalent HIV-1
subtype in the United States and Western Europe. Major-
ity of HIV strains in developing countries are non-Subtype
B. There is hence less data on resistance patterns in such
settings. There are reports that non-B HIV-1 strains carry
pol gene polymorphisms that may result in lower suscepti-
bility to ART compounds than in subtype B [6]. In Kenya,
several studies have been done to document drug resist-
ance among drug-naïve [7,8] as well as drug experienced
HIV-1 infected individuals [9]. But to date, scanty data is
available on the prevalence of drug resistance among
HIV-1-infected drug-naïve antenatal clinic attendees in
rural settings. It has been shown that transmitted drug
resistance mutations impact negatively on first-line ART
outcomes [9]. This study was therefore carried out to elu-
cidate the patterns of drug resistance-associated mutations
among drug-naïve antenatal clinic attendees in Kenya, es-
pecially with the rapid expansion of ART.
Methods
Study subjects and specimens
From April 2005 to July 2006, 298 HIV-positive women
attending antenatal clinics in Nandi Hills, Kapsabet,
and Kitale hospitals were included in this study. After
informed consent, participants’ demographic data was
obtained using a structured questionnaire. Prior ex-
posure to ART and specifically single dose nevirapine
was also explored. The study participants have been pre-
viously described [10]. Routine investigations in Kenyan
antenatal clinics constitute blood withdrawal for HIV
testing.
From each mother, five milliliters of venous blood was
collected in sterile vacutainer tubes containing EDTA as
anticoagulant. The blood was separated into plasma and
buffy coats within six hours by centrifugation. Two ali-
quots of each sample were immediately kept at −80°C.
The samples were later transported under refrigeration
(with ice packs) by overnight courier to the laboratory
for analysis.
This study was approved by the Kenya Medical Research
Institute Scientific Steering Committee and Ethical Review
Board. The study was conducted according to the national
and international regulations governing the use of human
subjects in biomedical research.
HIV-1 serology
HIV antibodies were tested by rapid tests as per the
guidelines laid down by the Ministry of Health, Kenya.
Rapid parallel testing was carried out using Determine™
HIV-1/2 (Abbott Diagnostic Division) and Uni-Gold™
HIV (Trinity Biotech) test kits. In case of discrepancy,
Bioline HIV 1/2 3.0 (Standard Diagnostics) was used as
a tiebreaker.
Extraction of nucleic acids, polymerase chain reaction
(PCR) and sequencing
HIV-1 RNA was extracted from 200 μl of plasma using
BioMérieux EasyMAG® robot. An initial One-Step RT-
PCR for the pol (PR codons 1–99 and RT codons 1–237)
region was performed using the Qiagen One-Step RT
PCR Kit followed by a nested PCR amplification using
in-house group M consensus primers as previously de-
scribed [9,11].
PCR products were purified using MultiScreen Separa-
tions System. Amplicons were sequenced employing
BigDye chemistry (Applied Biosytems, Foster City, CA,
USA) using in-house primers on an ABI Prism 3130XL
sequencer (Applied Biosystems, Foster City, CA, USA).
Generated sequences were assembled using Seqscape v2.5
(Applied Biosystems). The resulting sequences were edited
using sequence alignment editor software BioEdit v7.0.5
(Ibis Therapeutics, Carlsbad, CA).
Drug resistance analysis
The edited sequences were analyzed using the WHO’s
list of drug resistance mutations for surveillance of
transmitted HIV-1 drug-resistance [12]. This analysis list
contains 93 mutations of which 34 are NRTI-associated
resistance mutations at 15 RT positions, 19 are NNRTI-
associated resistance mutations at 10 RT positions and
40 PI-associated resistance mutations at 18 protease
positions. The Stanford University HIV Drug Resistance
Database (http://sierra2.stanford.edu/sierra/servlet/JSierra)
was initially used to determine possible mutations. The
mutation points associated with drug resistance were then
documented.
HIV subtyping
Multiple alignments of the generated sequences with
reference sequences from the HIV sequence database
(Los Alamos National Laboratory) were performed using
Clustal W [13]. Genetic distances were calculated by the
Kimura two-parameter method [14] and the phylogen-
etic tree constructed by the neighbor-joining method
[15] with its reliability being estimated by 1000 bootstrap
replications. The REGA HIV-1 subtyping tool (http://
hivdb.stanford.edu/RegaSubtyping/) was used to deter-
mine the HIV-1 subtype alongside the HIV drug resist-




Of the 298 plasma samples available, 44 plasma samples
did not amplify due to possible low viral load or primer
Kiptoo et al. BMC Infectious Diseases 2013, 13:517 Page 2 of 4
http://www.biomedcentral.com/1471-2334/13/517
mismatches; 37 were excluded because they were ob-
tained from mothers who had been exposed to single
dose nevirapine. Two hundred and fifty four samples
were successfully amplified. However, 29 samples did
not yield the desired sequence length and were therefore
excluded from the final analysis. A final total of 188
HIV-1 pol gene sequences were successfully obtained
from blood samples of drug-naïve antenatal clinic at-
tendees; 65 from Nandi hills, 71 from Kitale, and 52
from Kapsabet.
HIV-1 subtype distribution
All the 188 sequences were identified as belonging to
HIV-1 group M. They were classified into the following
subtypes and circulating recombinant forms (CRFs): sub-
types A1 (n=117, 62.2%), A2(n=2, 1.1%), D (n=27, 14.4%),
C (n=13, 6.9%), G (n = 3, 1.6%), and possible recombinants
(n=26, 13.8%). The possible recombinants included
AC (n=3, 1.6%), AD (n=20, 10.6%), CD (n=2, 1.1%),
CRF10_CD (n = 1, 0.5%). Distribution of the HIV-1
subtypes in the three hospitals is summarized in
Table 1.
Protease inhibitor (PI) resistance-associated mutations
A major protease inhibitor-associated mutation was
found in one strain. This occurred at amino acid pos-
ition 46 in the HIV protease gene (i.e. M46L). Other
major protease inhibitor-associated mutations (D30N,
V32I, I47A/V, G48V, I50L/V, I54L/M, L76V, V82A/F/L/
S/T, I84V, and L90M) were not detected among the
women from the three hospitals. However, minor PI as-
sociated mutations detected included L10I (12), L10V
(10), L10I/V (3), L33F (1), and L33I (1). Thus all the pa-
tients were susceptible to available protease inhibitor
regimens.
Reverse transcriptase inhibitor (RTI) resistance-associated
mutations
Primary mutations associated with nucleoside RTI
(NRTI), K65R, D67N and K70E were detected in one case
each. A secondary mutation, T69S was detected in three
women. A mutations associated with non-nucleoside RTI
(NNRTI), K101E was detected in one case. Overall, 3.2%
of the blood samples from antenatal clinic attendees of
the three hospitals harbored drug resistance mutations.
Discussion
In this study we showed a high diversity of HIV-1 sub-
types circulating in the north rift valley region of Kenya.
It has been shown previously that HIV-1 diversity is high
in Kenya, with a dominance of subtype A1 [7,16]. Simi-
larly, majority of the mothers in this study were infected
with HIV-1 subtype A1. Although consistent with other
findings in which subtype A1 has been reported to be
the major subtype in circulation, the percentage of sub-
type A1 in this population was lower than what was
found in another independent study along the coastal
region of Kenya [16]. Nonetheless, there appear to be
more recombinants in this population suggesting pos-
sible evolution and diversification of prevalent subtypes.
We have further shown that the prevalence of drug re-
sistance among drug naïve antenatal clinic attendees in
north rift valley in 2006 was 3.2%. This was below the
WHO threshold of 5%.
As in other cross-sectional studies, this study had limi-
tations. One, the samples were anonymously collected
with no baseline information regarding demographics,
viral load or CD4 data that would have enabled us to
further categorize the patients for better management
later. Two, only positive samples were analyzed for sub-
types and drug resistance; site prevalence analysis of
HIV in the studied population was not possible. Three,
at the time of sample analysis, the ART coverage in
Kenya was <20%. The coverage today is > 60%. The case
scenario at that time may not be reflective of current
status of transmitted resistance. Four, patients in this
study did not meet the WHO standard for surveillance
drug resistance; it would be hard to establish a definite
result on transmitted resistance mutations in such pa-
tients with chronic HIV infection. In our setting the
study may have underestimated the rate of transmission
in this part of Kenya. However, this points to the need
for rapid surveillance of resistance among drug naïve in-
dividuals in Kenya. All notwithstanding, this study may
be a representative of the situation on ART naïve indi-
viduals and prevalent subtypes in this region at that
time. From our observation, it is likely and possibly true
that ART in this population had not gained much
ground. Furthermore, if there might have been transmit-
ted mutations, the population sequencing methodology
Table 1 Distribution of HIV-1 subtypes among HIV posi-
tive drug naïve Antenatal clinic attendees in rural Kenya
Subtype Hospital/Facility Total
SNH n=65 KAPH n=52 KTL n=71
A1 39 31 47 117
A2 1 0 1 2
C 4 2 7 13
D 13 10 4 27
G 1 1 1 3
AC 1 0 2 3
AD 5 7 8 20
CD 1 0 1 2
CRF 10_CD 0 1 0 1
SNH: South Nandi Hospital; KAPH: Kapsabet hospital; KTL: Kitale.
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that we employed might have left out mutations that
occur as minor populations.
This study provides the first results on potential resist-
ance of HIV-1 to antiretroviral drugs among untreated
pregnant women in Kenya. The low frequency of drug
resistance mutations in this study is similar with previ-
ous studies conducted among drug naïve antenatal clinic
attendees in countries close to Kenya, such as Tanzania
and Ethiopia [17,18].
Conclusion
As seen from this study, continuous HIV-1 characterization
and evaluation of drug resistance before and during HIV
therapy among antenatal clinic attendees in rural set ups
would be important in guiding patient directed treatment.
This will eventually help to avert the envisaged treatment
failure among patients who are increasingly presenting with
diverse viral subtypes with limited ART options.
Sequence data
Sequences obtained in this study were deposited in
the GenBank under accession numbers: KC516873 -
KC517060.
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